"Our study shows that clinically significant placebo effects can be produced even when patients are told that they are being given placebos."
Because the increased cytokine levels in the acute phase of herpes zoster are assumed to be a potential mechanism for inducing PHN, the early suppression of these cytokines by LLLT may help prevent the development of PHN.
"Dose-extending placebo use is based on learning principles and schedules of reinforcement, so that conditioned stimuli acquire properties and characteristics of unconditioned stimuli," Dr Colloca told Clinical Pain Advisor.
Clinical Pain Advisor Articles
- Chronic Pain May Be a Contributing Factor to Suicide
- Supervised Injection Sites: Facts, Information, Pros, and Cons
- Striking a Balance Between Opioid Surveillance and Patient Privacy
- Demographic Characteristics of Pregnant Women With Opioid Use Disorder
- Effects of Mindfulness Therapy, Pharmacologic Prophylaxis on Catecholamine Levels in Migraine
- Perioperative Pain Management in Patients With Opioid Use Disorder
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- Antidepressant Effects of Ketamine Appear to Require Opioid System Activation
- Reviewing the Efficacy of Intrathecal Morphine, Ziconotide for Cancer- and Noncancer Chronic Pain
- Seven-Item Pain Intensity Measure Reliable in Individuals With Dementia
- Factors Associated With Suboptimal Interscalene Brachial Plexus Block for Arthroscopy
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- Scholarship Support Limited for Veterans Enrolling in MD Programs
- Alpha and Beta Band Activity in MS-Related Chronic Pain
- New Opioid-Induced Constipation Management Guidelines Available